5YL Stock Overview
A medical device company, together with its subsidiaries, engages in the development, marketing, and sale of medical cooling systems for the healthcare sector in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BrainCool AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.12 |
| 52 Week High | SEK 0.49 |
| 52 Week Low | SEK 0.097 |
| Beta | 1.65 |
| 11 Month Change | -18.73% |
| 3 Month Change | -31.01% |
| 1 Year Change | -71.01% |
| 33 Year Change | -82.57% |
| 5 Year Change | n/a |
| Change since IPO | -88.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5YL | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0.3% | -1.0% | -0.02% |
| 1Y | -71.0% | -7.3% | 8.2% |
Return vs Industry: 5YL underperformed the German Medical Equipment industry which returned -8.4% over the past year.
Return vs Market: 5YL underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 5YL volatility | |
|---|---|
| 5YL Average Weekly Movement | 7.9% |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5YL's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5YL's weekly volatility has decreased from 16% to 8% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 20 | Jon Berg | braincoolinc.com |
BrainCool AB (publ), a medical device company, together with its subsidiaries, engages in the development, marketing, and sale of medical cooling systems for the healthcare sector in Sweden. The company offers products for medical cooling treatments for a range of diseases, including stroke, sudden cardiac arrest, oral mucositis, and migraine. It provides BrainCool and RhinoChill systems that facilitates rapid medical cooling treatment in an emergency setting and ensures the continuum of care; Cooral system provides medical professionals an easy way to reduce the risk of oral mucositis; and IQool system offers an easy-to-use intuitive interface, informative graphics, and an automatic feedback loop allowing clinicians to manage their patient rather than a device.
BrainCool AB (publ) Fundamentals Summary
| 5YL fundamental statistics | |
|---|---|
| Market cap | €34.77m |
| Earnings (TTM) | -€5.01m |
| Revenue (TTM) | €3.54m |
9.8x
P/S Ratio-6.9x
P/E RatioIs 5YL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5YL income statement (TTM) | |
|---|---|
| Revenue | SEK 40.67m |
| Cost of Revenue | SEK 29.14m |
| Gross Profit | SEK 11.54m |
| Other Expenses | SEK 69.12m |
| Earnings | -SEK 57.58m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 10, 2025
| Earnings per share (EPS) | -0.23 |
| Gross Margin | 28.37% |
| Net Profit Margin | -141.57% |
| Debt/Equity Ratio | 0% |
How did 5YL perform over the long term?
See historical performance and comparison